Ipsen says its partner, Lexicon Pharmaceuticals, announces positive results from Telestar Phase 3 study
Monday, August 03, 2015
Ipsen's partner, Lexicon Pharmaceuticals, announces positive results from Telestar Phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not ade.
Telotristat etiprate met primary endpoint.
reuters.com
